Stellaris Pharmaceuticals

Stellaris Pharmaceuticals is a Danish biotechnology company focused on developing innovative local treatments for severe postpartum hemorrhage and other obstetric bleedings. Founded in 2012, the company leverages the physiological mechanism of tissue factor complexing with recombinant activated factor VII (rFVIIa) to achieve localized hemostasis at the placenta site. By applying rFVIIa topically rather than intravenously, Stellaris aims to significantly reduce bleeding after delivery without exposing patients to the risk of systemic thrombotic events. The company's clinical pipeline includes a completed proof-of-concept study in placenta previa and a clinical trial evaluating local rFVIIa treatment for severe postpartum hemorrhage.